Biogen’s New Alzheimer’s Drug Meets Slow Rollout
The drugmaker’s revenue from the drug, Aduhelm, was $300,000 in the first full quarter since its approval, a figure well below analyst expectations. Sales could be minimal through the end of the year, the company said.
This post was originally published on Market Watch
